Payment overview · 2025
General Payments
$3,829.66
75 reported records · 24 companies
Healthcare provider profile · identity verified
Navin Budhwani, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · OAKLAND, NJ · NPI 1104990266
Verified facts
What the public records show
CMS Open Payments records show Navin Budhwani, MD received $3,829.66 in general payments during 2025 across 75 reported records.
CVRx, Inc. accounted for 17.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 395 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Jardiance by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 395 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| CVRx, Inc. | Unresolved — no canonical attribution shown | $666.74 | 17.4% | 3 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $372.00 | 9.7% | 4 | 2025 |
| Terumo Medical Corporation | Unresolved — no canonical attribution shown | $327.12 | 8.5% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$293.31 | 7.7% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $287.62 | 7.5% | 10 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $270.46 | 7.1% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $256.49 | 6.7% | 4 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $251.32 | 6.6% | 5 | 2025 |
| Cleerly, Inc. | Unresolved — no canonical attribution shown | $226.21 | 5.9% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $191.18 | 5.0% | 10 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $157.65 | 4.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $75.51 | 2.0% | 4 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $62.78 | 1.6% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $60.75 | 1.6% | 4 | 2025 |
| BIOTRONIK INC. | Unresolved — no canonical attribution shown | $52.29 | 1.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $49.84 | 1.3% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $49.09 | 1.3% | 2 | 2025 |
| BridgeBio Pharma, Inc. | Unresolved — no canonical attribution shown | $37.07 | 1.0% | 2 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $33.24 | 0.9% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $33.02 | 0.9% | 2 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $24.00 | 0.6% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $18.36 | 0.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.30 | 0.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.31 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,563.39 | 74 |
| Travel and Lodging | $266.27 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $666.74 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $287.62 | 10 | 2025 |
Source payment records
|
|||||
| Technical Education MRI Normalized: technical education mri |
Device | Philips North America LLC | $270.46 | 2 | 2025 |
Source payment records
|
|||||
| Cleerly Ischemia Normalized: cleerly ischemia |
Device | Cleerly, Inc. | $226.21 | 3 | 2025 |
Source payment records
|
|||||
| Cleerly Labs Normalized: cleerly labs |
Device | Cleerly, Inc. | $226.21 | 3 | 2025 |
Source payment records
|
|||||
| NAVICROSS Normalized: navicross |
Device | Terumo Medical Corporation | $216.82 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $191.18 | 10 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $157.65 | 1 | 2025 |
Source payment records
|
|||||
| HAWKONE Normalized: hawkone |
Device | Medtronic, Inc. | $140.41 | 1 | 2025 |
Source payment records
|
|||||
| COROFLOW Normalized: coroflow |
Device | Abbott Laboratories | $138.16 | 1 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $129.64 | 4 | 2025 |
Source payment records
|
|||||
| GLIDESHEATH SLENDER Normalized: glidesheath slender |
Device | Terumo Medical Corporation | $110.30 | 1 | 2025 |
Source payment records
|
|||||
| HYDROPEARL Normalized: hydropearl |
Device | Terumo Medical Corporation | $110.30 | 1 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $108.16 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $89.11 | 5 | 2025 |
Source payment records
|
|||||
| NAVITOR Normalized: navitor |
Device | Abbott Laboratories | $62.04 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $60.75 | 4 | 2025 |
Source payment records
|
|||||
| BIOMONITOR Normalized: biomonitor |
Device | BIOTRONIK INC. | $52.29 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $49.84 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $49.09 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $39.83 | 2 | 2025 |
Source payment records
|
|||||
| Attruby Normalized: attruby |
Drug | BridgeBio Pharma, Inc. | $37.07 | 2 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $35.68 | 2 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $33.24 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $33.02 | 2 | 2025 |
Source payment records
|
|||||
| PRESSUREWIRE Normalized: pressurewire |
Device | Abbott Laboratories | $31.37 | 1 | 2025 |
Source payment records
|
|||||
| SILVERHAWK Normalized: silverhawk |
Device | Medtronic, Inc. | $30.15 | 1 | 2025 |
Source payment records
|
|||||
| THORATEC HEARTMATE 3 LVAS IMPLANT KIT Normalized: thoratec heartmate 3 lvas implant kit |
Device | Abbott Laboratories | $24.92 | 1 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE MVP VVCS 6-12F Normalized: cardiva vascade mvp vvcs 6 12f |
Device | CARDIVA MEDICAL, INC. | $24.00 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $18.36 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.30 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.31 | 1 | 2025 |
Source payment records
|
|||||
| ABRE Normalized: abre |
Device | Medtronic, Inc. | $14.59 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $13.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 395 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
395 | 92 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
43 | 14 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
39 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
395 | 92 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 800 | 239 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 580 | 175 |
| Clopidogrel | Clopidogrel Bisulfate | 484 | 147 |
| Atorvastatin Calcium | Atorvastatin Calcium | 445 | 134 |
| Eliquis | Apixaban | 395 | 92 |
| Amlodipine Besylate | Amlodipine Besylate | 298 | 95 |
| Lisinopril | Lisinopril | 294 | 92 |
| Losartan Potassium | Losartan Potassium | 250 | 75 |
| Metoprolol Tartrate | Metoprolol Tartrate | 153 | 49 |
| Pravastatin Sodium | Pravastatin Sodium | 148 | 42 |
| Carvedilol | Carvedilol | 139 | 36 |
| Valsartan | Valsartan | 135 | 44 |
| Simvastatin | Simvastatin | 129 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 120 | 37 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 116 | 35 |
| Ramipril | Ramipril | 111 | 32 |
| Brilinta | Ticagrelor | 81 | 18 |
| Furosemide | Furosemide | 79 | 34 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 76 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 72 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 66 | 21 |
| Xarelto | Rivaroxaban | 65 | 19 |
| Levothyroxine Sodium | Levothyroxine Sodium | 64 | 20 |
| Nebivolol Hcl | Nebivolol Hcl | 64 | 19 |
| Atenolol | Atenolol | 63 | 18 |
| Repatha Sureclick | Evolocumab | 59 | 12 |
| Digoxin | Digoxin | 54 | 11 |
| Spironolactone | Spironolactone | 53 | 19 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 51 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 46 | 11 |
| Tamsulosin Hcl | Tamsulosin Hcl | 45 | 14 |
| Icosapent Ethyl | Icosapent Ethyl | 43 | 16 |
| Jardiance | Empagliflozin | 43 | 14 |
| Ezetimibe | Ezetimibe | 41 | 12 |
| Metformin Hcl | Metformin Hcl | 40 | 15 |
| Entresto | Sacubitril/Valsartan | 39 | 11 |
| Alprazolam | Alprazolam | 38 | 13 |
| Celecoxib | Celecoxib | 38 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 38 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | suppressed |
| Vascepa | Icosapent Ethyl | 32 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Omeprazole | Omeprazole | 25 | suppressed |
| Telmisartan | Telmisartan | 24 | suppressed |
| Torsemide | Torsemide | 24 | 11 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 23 | suppressed |
| Famotidine | Famotidine | 22 | suppressed |
| Irbesartan | Irbesartan | 22 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 22 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | 12 |
| Potassium Chloride | Potassium Chloride | 19 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 18 | suppressed |
| Allopurinol | Allopurinol | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Cartia Xt | Diltiazem Hcl | 15 | suppressed |
| Ozempic | Semaglutide | 15 | suppressed |
| Dofetilide | Dofetilide | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,829.66 · 75 records | CVRx, Inc. | ABRE, AMVUTTRA, Attruby, BIOMONITOR, Barostim Neo System, CAMZYOS, CARDIVA VASCADE MVP VVCS 6-12F, COROFLOW, Cleerly Ischemia, Cleerly Labs, Cologuard Collection Kit, ELIQUIS, FUROSCIX, GLIDESHEATH SLENDER, HAWKONE, HYDROPEARL, Kerendia, LEQVIO, NAVICROSS, NAVITOR, NEXLETOL, NURTEC ODT, PRESSUREWIRE, REPATHA, SAPIEN 3 Ultra RESILIA, SILVERHAWK, SYMPLICITY G3, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, THORATEC HEARTMATE 3 LVAS IMPLANT KIT, Technical Education MRI, VYNDAQEL, WATCHMAN FLX, Wegovy, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error